The present disclosure relates to MMP8 inactivating antigen binding proteins, preferably antigen binding proteins comprising an amino acid sequence that comprises (4) framework regions and (3) complementary determining regions; it relates further to the use of such antigen binding proteins to treat inflammation, such as but not limited to systemic inflammatory response syndrome, sepsis, LPS induced inflammation, renal ischemia/reperfusion injury, ventilation induced lung injury, periodontal inflammation, rheumatoid arthritis, multiple sclerosis, ankylosing spondylitis, lyme arthritis and osteoarthritis.
MMP8 INACTIVATING ANTIGEN BINDING PROTEINS